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bjectives In this retrospective study, we examined the incidence of post-procedural conduction
bnormalities and the need for pacing in patients undergoing percutaneous implantation of the
ortic valve.
ackground Safety and feasibility studies have suggested anecdotally the occurrence of conduction
bnormalities and requirements for pacing after percutaneous implantation of the aortic valve.
ethods We examined the standard 12-lead electrocardiograms (ECGs) of 40 consecutive patients
n whom a CoreValve Revalving System (CoreValve, Paris, France) was implanted between November
005 and March 2008. We examined the 12-lead ECG before treatment, after treatment, and at
-month follow-up. We documented the requirements for temporary or permanent pacemaking.
esults The mean age of patients was 82  7 years. Post-procedural mortality at 72 h was 0%.
here was a signiﬁcant increase in the frequency of left bundle branch block (LBBB) after percutane-
us aortic valve replacement (15% before treatment vs. 55% after treatment, p  0.001). Although
he incidence of LBBB had decreased after follow-up of 1 month, it did not reach statistical signiﬁ-
ance, with the proportion decreasing from 55% to 48% (p  0.63). The only 2 patients with pre-
reatment right bundle branch block became dependent on temporary pacing immediately after
alve implantation and subsequently needed permanent pacing. A temporary and permanent pace-
aker was required in 20% and 18% of patients, respectively.
onclusions In this study, there was a signiﬁcant increase in the frequency of LBBB after percutane-
us insertion of the aortic valvar prosthesis. Patients with pre-existing right bundle branch block
ay be at risk for the development of complete heart block and subsequent need for
acing. (J Am Coll Cardiol Intv 2008;1:310–6) © 2008 by the American College of Cardiology
oundation
rom the *Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands; †Cardialysis BV,
otterdam, the Netherlands; and the ‡Department of Pediatric Cardiology, Institute of Child Health, London, United Kingdom.anuscript received April 15, 2008; accepted April 28, 2008.
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311ortic valvar stenosis is well recognized as being associated
ith abnormalities of cardiac conduction (1,2). In particu-
ar, electrophysiologic studies have shown prolonged PR,
H, and HV intervals in these patients (3,4). The incidence
f intraventricular conduction defects after surgical replace-
ent of the aortic valve has been reported in as many as 33%
f patients, and has been associated with an increased
ncidence of adverse events (5,6). Furthermore, a permanent
acemaker is required in approximately 3% to 8% of these
atients (7–13). The occurrence of conduction abnormalities
fter surgical replacement of the aortic valve is not surprising
hen one considers the anatomical proximity of the conduc-
ion system to the aortic valve. Surgical trauma to the ventric-
lar conduction system, as well as myocardial ischemia, are
onsidered to be key factors in the development of these
bnormalities.
Percutaneous replacement of the aortic valve provides a
ew alternative for patients with severe aortic valvar stenosis
onsidered to be at high or prohibitive surgical risk. Studies
oncerning the safety and feasibility of the procedures have
ow been published (14–16). Initial reports have suggested
necdotally the occurrence of conduction abnormalities and
equirements for pacing (15–17) after percutaneous replace-
ent of the aortic valve. In this retrospective study, we
xamined in more detail the incidence of early post-
rocedural conduction abnormalities identified on 12-lead
lectrocardiographic tracings and the need for a temporary
r permanent pacing in patients undergoing percutaneous
eplacement of the aortic valve using the CoreValve Re-
alving System (CoreValve, Paris, France).
ethods
atients. We reviewed the records of 40 consecutive pa-
ients with aortic stenosis in whom a CoreValve Revalving
ystem was implanted between November 2005 and March
0, 2008. Patients were referred for percutaneous aortic
alvar insertion after a cardiologist and cardiac surgeon
eached consensus that surgical replacement would be asso-
iated with either high or prohibitive risk. The logistic
uroScore was used to estimate the baseline surgical oper-
tive risk (18).
The criteria for inclusion and exclusion for the implan-
ation of the CoreValve ReValving System have been
escribed elsewhere. In brief, patients were included if they
ad echocardiographic measurements demonstrating severe
ative valvar stenosis, with an area 1 cm2, or 0.6
m2/m2, with or without aortic regurgitation; a diameter of
he basal orifice of the stenosed valve of between 20 mm and
7 mm; and a diameter at the sinutubular junction equal to
r 43 mm.
escription of the device and procedure. Details of the
evice, and the technical aspects of the procedure, have been
reviously published (19). The prosthesis consists of a 1elf-expanding nitinol tri-level frame to which is secured a
rileaflet bioprosthetic porcine pericardial tissue valve. Cur-
ently, the prosthesis is available in sizes of 26 and 29 mm.
election of the device depends on measurements of the
ortic valvar complex obtained by echocardiography, an-
iography, or multislice computed tomography.
Balloon valvotomy was required before implantation.
ositioning and deployment of the device was performed
olely under fluoroscopic and angiographic guidance. On the
asis of the recommendations at the time, the ventricular edge
f the valve frame was implanted approximately 10 to 12 mm
elow the lower edge of the right noncoronary cusp (i.e., basal
ttachments of the aortic valvar leaflets) as identified on
ontrast aortography. In 29 patients (70%), we implanted the
6-mm device; later, when it became available, we used the
9-mm device in 11 patients. In 4 patients, because of
nappropriate positioning of the first device, we implanted a
econd device of 26 mm in diameter.
ollection of ECG and pacemaking data. Electrocardio-
raphic tracings obtained before and after treatment, along
ith 1-month standard recordings, were interpreted in our
ore laboratory, where we analyzed the recordings for
hythm, heart rate (beats/min), PR, QRS, and corrected
T intervals (all in millisec-
nds), and presence of second-
r third-degree atrioventricular
AV) block. Diagnostic criteria
ecommended by the World
ealth Organization and Inter-
ational Society and Federation
or Cardiology Task Force (20)
as used to code for left and right fascicular hemiblock and
eft and right bundle branch block.
In addition, an electronic 3-lead rhythm strip was con-
inuously recorded during the procedure and stored elec-
ronically. The timing of any increase in the width of the
RS segment during the procedure was recorded from a
ingle-lead surface tracing obtained during fluoroscopy. We
ocumented the requirements after the procedure for tem-
orary or permanent pacemaking.
istance of the aortic prosthesis within the left ventricular
utﬂow tract. Using quantitative angiographic techniques
CAAS 5.4, Pie Medical, Maastricht, the Netherlands), we
easured the distance (in millimeters) from the lower edge
f the noncoronary cusp to the ventricular (i.e., proximal)
nd of the frame. We examined this distance to investigate
he association between the depth of implantation of the
ortic prosthesis within the left ventricular outflow tract and
he development of conduction abnormalities.
tatistical analysis. Continuous variables are presented as
eans (SD). Categorical variables are presented as fre-
uencies and percentages. For continuous variables, paired
omparisons between pre-treatment and post-treatment or
Abbreviations
and Acronyms
AV  atrioventricular
ECG  electrocardiogram
LBBB  left bundle branch
block-month follow-up and between post-treatment and
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312-month follow-up were done with a Wilcoxon signed rank
est. For binomial variables, paired comparisons between
re-treatment and post-treatment or 1-month follow-up
nd between post-treatment and 1-month follow-up were
one with the McNemar test and conducted by exact
ethods. For the comparison of the mean distance (in
illimeters) of the aortic prosthesis within the left ventric-
lar outflow tract between those patients with and those
ithout new-onset left bundle branch block (LBBB), the
ndependent sample t test was used. Statistical significance
as assumed for p values of0.05. All statistical analyses were
erformed with SPSS software version 12 (SPSS Institute,
hicago, Illinois).
esults
aseline characteristics of our 40 patients are summarized in
able 1, with 1 patient dying 6 days after implantation as a
onsequence of procedurally related cardiac tamponade.
welve-lead ECG evaluation. The flow diagram (Fig. 1)
hows the number of electrocardiograms available for inter-
retation, and time to follow-up, with results of analysis
hown in Table 2.
HYTHM. The majority of patients (67%) were in sinus
hythm before the procedure, but this number decreased
ignificantly after insertion, with the change being main-
Table 1. Clinical Characteristics (n  40)
n (%)
Age (yrs), mean  SD 82 7
Male 20 (50)
Coronary artery disease 15 (38)
1-VD 6 (15)
2-VD 1 (3)
3-VD 8 (20)
History of myocardial infarction 8 (20)
History of percutaneous coronary intervention 8 (20)
History of coronary artery bypass 12 (31)
History of heart failure 10 (26)
Left ventricular ejection fraction %, mean  SD 4112
Permanent pacemaker 1 (3)
Diabetes 12 (31)
Hypertension 12 (31)
Hypercholesterolemia 7 (17)
Renal failure 17 (43)
Smoker 2 (6)
Aortic valve area (cm2), mean  SD 0.75 0.23
LVOT diameter (mm), mean  SD 21 2
Mitral annular calciﬁcation 23 (57%)
Prosthesis inﬂow size
26-mm 29 (73%)
29-mm 11 (27%)L
LVOT left ventricular outflow tract; VD vessel disease.ained at 1-month follow-up (67% vs. 51%, p  0.001 and
7% vs. 55%, p  0.001, respectively). Approximately
ne-third of the patients had atrial fibrillation at baseline
nd atrial fibrillation of new onset was noted in 2 patients.
RS DURATION. The mean QRS duration increased after
nsertion of the device (111  27 ms vs. 150  32 ms, p 
.001) and, subsequently, decreased significantly from post-
reatment to 1-month follow-up (150 32 ms vs. 134 29
s, p  0.001) (Table 2). Despite the subsequent decrease,
he difference from baseline readings at 1-months follow-up
emained significant (111  27 ms vs. 134  29 ms, p 
.001).
UNDLE BRANCH BLOCK AND AV BLOCK. There was a sig-
ificant increase in the frequency of LBBB after insertion of
he device, from 15% before insertion to 55% after insertion
p  0.001). Although the incidence of LBBB had de-
reased after follow-up of 1 month, it did not reach
tatistical significance, with the proportion decreasing from
5% to 48% (p  0.63). Furthermore, the increase in the
requency of LBBB remained significant at 1-month
ollow-up (48% vs. 15%, p  0.02) (Table 2). One patient
ith incomplete block after insertion had progressed to
omplete LBBB after 1 month, whereas 1 patient with
ew-onset LBBB after insertion had resolved during
ollow-up.
The distance from the lower edge of the noncoronary
usp to the proximal edge (i.e., ventricular end) of the frame
f the prosthesis (Fig. 2) was measured to be a mean of 10.3
2.7 mm (range 6.7 to 14.6 mm) in those who developed
40 consecutive patients underwent PAVR  
Pre-treatment ECG (n = 39/40) 
Performed 21  ± 50 days pre-intervention  
Post-treatment ECG (n= 39/40) 
Performed 3 ± 2 days post intervention  
1-month follow-up ECG (n = 27/ 40) 
Performed 42 ± 23 days post-intervention  
Figure 1. Flow Diagram
The diagram demonstrates the number of 12-lead electrocardiograms (ECG)
available for interpretation and the mean time to follow-up expressed in
days (mean  SD). PAVR  percutaneous aortic valve replacement.BBB of new onset and distinctively after valve implanta-
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313ion and 5.5  3.4 mm (range 0.7 to 12.2 mm) in those
ithout the development of LBBB (p  0.005).
There was no clinically significant change in mean PR
nterval during the period of follow-up (Table 2). We found
Figure 2. Quantitative Angiographic Measurement
A representative example of the measurement of the distance from the
lower edge of the noncoronary cusp to the proximal (or ventricular) end of
Table 2. Electrocardiogram Interpretation
Before Treatment
(n  39)
After Treatment
(n  39)
1 Month
(n  27)
Rhythm, n (%)
Sinus 26 (67) 20 (51) 15 (55)
Atrial ﬁbrillation 11 (27) 13 (33) 7 (26)
Pacemaker 1 (3) 5 (13) 4 (15)
Other 1 (3) 1 (3) 1 (3)
Heart rate (beats/min) 77 14 73 18 77 15
PR interval (ms) 165 62 177 55 186 36
QRS width (ms) 111 27 150 32 134 29
QT interval (ms) 419 29 458 44 429 33
Hemiblock, n (%)
None 31 (80) 38 (95) 26 (96)
Anterior 7 (17) 1 (3) 1 (4)
Posterior 1 (3) 0 (0) 0 (0)
Bundle branch block, n (%)
None 26 (67) 12 (31) 11 (41)
Left 6 (15) 22 (55) 13 (48)
Right 2 (5) 3 (8) 1 (4)
Incomplete left 4 (10) 1 (3) 1 (4)
Incomplete right 1 (3) 1 (3) 1 (4)a
the frame of the valve prosthesis is shown.1%, 26%, and 21% of patients with first-degree AV block
efore insertion, immediately after insertion, and after
ollow-up, respectively (p  0.766). Second-degree AV
lock type I was identified in 1 patient after follow-up.
iming of electrocardiographic changes during the proce-
ure. During the procedure, widening of the QRS complex
f new onset was noted in 20 of 40 patients (50%). In the
ajority of patients (70%), the widening occurred distinc-
ively after implantation of the device and in the remaining
0%, occurred before implantation but after percutaneous
ortic balloon valvotomy or guidewire crossing of the native
ortic valve.
equirements for pacemaking. One patient had a perma-
ent pacemaker implanted prior to the procedure. After
mplantation of the device, temporary pacing was required
n 8 patients (20%) and permanent pacing was required in 7
atients (18%). One-half of patients with requirement for
emporary pacing subsequently had implantation of a per-
anent pacemaker. The only 2 patients with right bundle
ranch block before insertion of the device both developed
hird-degree AV block and needed temporary pacing im-
ediately after implantation followed by permanent pacing.
ermanent pacemakers were implanted at a median of 6
ays, with a range from 4 to 47 days.
iscussion
ur results show that there is an increase of 40% in the
ccurrence of LBBB after percutaneous insertion of the
alue Before Treatment
s. After Treatment
p Value After Treatment
vs 1-Month Follow-Up
p Value Before Treatment
vs. 1-Month Follow-Up
0.001 1.00 0.001
1.00 1.00 0.50
0.13 1.00 0.25
1.00 1.00 1.00
0.96 0.51 0.46
0.05 0.29 0.84
0.001 0.001 0.001
0.001 0.001 0.15
0.02 1.00 0.63
0.03 1.00 1.00
1.00 n/a 1.00
0.004 0.25 0.07
0.001 0.63 0.02
1.00 1.00 1.00
1.00 1.00 0.63
1.00 1.00 1.00p V
vortic valvar prosthesis, and that approximately 1 of every 5
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314nd 1 of every 6 of our patients had requirements for a
emporary or permanent pacing, respectively.
bnormalities in conduction. Similar to the results in our
tudy, the first North American case series reported 4 of 11
atients (36%) in whom new-onset LBBB developed after
mplantation of the CoreValve Revalving System (17). To
he best of our knowledge, there have been no previous
tudies assessing abnormal cardiac conduction after 1 month
fter percutaneous aortic valvar insertion. The results of this
tudy suggest there is an improvement in intraventricular
onduction (i.e., decrease in QRS duration and frequency of
BBB) from the time after implantation to 1-month
ollow-up. Possible explanations include transient peri-
rocedural inflammation, edema, ischemia, or mechanical
tress with recovery of conduction.
The close anatomical relationship between the aortic
alvar complex and the branching AV bundle may provide
n explanation for the observed increase in LBBB after
ercutaneous aortic valvar implantation. Within the right
trium, the AV node is located within the triangle of Koch.
he Tendon of Todaro, the attachment of the septal leaflet
f the tricuspid valve, and the orifice of the coronary sinus
ll demarcate this important triangle. The apex of this
riangle is formed by the AV component of the membra-
ous septum, with the AV node located just inferior to the
pex. The node penetrates through the membranous septum
nd central fibrous body as the bundle of His, emerging in
Figure 3. Histological Section
The section demonstrates the piercing of the atrioventricular bundle
through the membranous septum, exiting superﬁcially along the crest of
the interventricular septum, and continuing to supply the left ventricle.
Reprinted with permission from Benson R. Wilcox, Andrew C. Cook, Robert
H. Anderson, Surgical Anatomy of the Heart, 3rd Edition (New York, NY:t
Cambridge University Press, 2005).he ventricles on the crest of the ventricular septum (Fig. 3),
here it gives rise to the fascicles of the left bundle branch.
When viewed from the left, the left bundle branch exits
pproximately 2 to 3 mm below the base of the interleaflet
riangle separating the noncoronary and right coronary
eaflets of the aortic valve, as shown exquisitely in the stellar
onograph of Tawara (Fig. 4) (21–23). In the present
tudy, the mean distance from the proximal (or ventricular)
nd of the frame of the valve prosthesis to the lower edge of
he noncoronary cusp was significantly greater in patients
ith new-onset LBBB than patients without new-onset
BBB (10.3  2.7 mm vs. 5.5  3.4 mm, respectively).
herefore, there exists the possibility of the aortic prosthesis
verlapping the left bundle branch and potentially crushing
t. Although it cannot be proven at this time, our results
uggest that positioning the aortic valve prosthesis in a more
uperior location within the left ventricular outflow tract
ay limit the risk of conduction abnormalities and poten-
ially the need for pacing. Indeed, no patient in our study
eveloped prosthesis-related LBBB when the proximal end
f the valve frame was positioned 6.7 mm from the lower
dge of the noncoronary cusp. Other potential sources of
nsult can include degeneration and calcification of the
onduction system, the mechanical or ischemic effects of
re-implantation balloon valvotomy, or the direct contact
nd trauma by catheters and guidewires with components of
Figure 4. Monograph of Tawara
The monograph shown demonstrates how the left bundle branch exits
below the base of the interleaﬂet triangle, separating the noncoronary and
right coronary leaﬂets of the aortic valve and fanning along the ventricular
septum to supply the left ventricle. Modiﬁed from Tawara (22).he conduction system.
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315In our study, one-third of the patients developed intra-
entricular conduction abnormalities of new onset after
ercutaneous aortic balloon valvotomy or with passage of
he guidewire across the native aortic valve. Similarly, an
nalysis of 207 patients who underwent mitral or aortic
alloon valvotomy showed an incidence of almost one-fifth
n new-onset intraventricular conduction defects after val-
otomy (24). Although yet to be investigated, strategies to
iminish the trauma imposed upon the conduction system
y percutaneous aortic balloon valvotomy may reduce the
isks of conduction abnormalities associated with these
rocedures. Such strategies may include limiting the size of
he balloon, limiting the depth of the balloon within the left
entricular outflow tract and keeping the number of pre- and
ost-valve implantation balloon valvuloplasties to a minimum.
In contrast, new conduction defects can develop in as
any as one-third of patients undergoing surgical replace-
ent of the aortic valve, with LBBB being the most
ommon abnormality (5,25–27). Although the significance
f LBBB after percutaneous aortic valve insertion is not yet
lear, new and persistent right or LBBB acquired after
urgical replacement has been associated with a significantly
ncreased risk of subsequent arrhythmic events, such as
yncope, AV dissociation, and sudden cardiac death (5).
ost of the events are thought to occur within the first year
f follow-up.
equirements for pacemaking. Approximately 1 of every 5
nd 1 of every 6 of our patients required a temporary or
ermanent pacing, respectively. Temporary pacing was re-
uired immediately after implantation in the 2 patients with
ight bundle branch block before insertion, and both pa-
ients subsequently needed permanent pacing. The high
ccurrence of LBBB of new onset in our cohort suggests
hat those with pre-existing right-bundle branch block need
o be closely monitored after implantation.
Previous studies have suggested that pacing may be
eeded after percutaneous valvar replacement. In the North
merican series, 3 of 11 patients (27%) had requirements
or permanent pacing after implantation of the CoreValve
evalving System (17). In 27 patients undergoing implan-
ation with the balloon-expandable Cribier-Edwards aortic
rosthesis, Cribier et el. (16) reported 1 patient who
eveloped third-degree heart block immediately after im-
lantation, with loss of temporary pacing resulting in death.
nother of their patients developed third-degree heart
lock 3 months after the procedure, with implantation of a
ermanent pacemaker complicated by pulmonary embolus
nd death. Webb et al. (15) described the development of
ransient complete heart block in only 1 of 50 patients being
mplanted with the Cribier-Edwards aortic prosthesis. At
ean follow-up of 75  55 days, they reported no further
ccurrences of conduction abnormalities or need for a
ermanent pacemaker (15). wThe occurrence of complete heart block and subsequent
eed for permanent pacing has been reported after aortic
alloon valvotomy but is rare (24). On the other hand,
omplete heart block can occur in approximately one-fifth
f patients immediately after surgical replacement of the
ortic valve (8). In approximately two-thirds of those
atients suffering this complication, it is a transient phe-
omenon. In general, between 3% and 8% of patients need
ermanent pacing. Specifically in the elderly, permanent
acing has been required in approximately 6% to 6.5%. Risk
actors for permanent pacing include age, additional valvar
isease, history of myocardial infarction, mitral annular
alcification, pre- and postoperative disease of the conduc-
ion system disease, repeat operations and multivalve sur-
ery (13,28–30).
tudy limitations. As with any retrospective analysis, our
tudy has its inherent limitations. We report from a single-
enter experience. In addition, 12 patients had not reached
-month follow-up at the time of this analysis. Although
imited by the small numbers, our results are hypothesis
enerating and possibly indicate the need for reappraisal of
he current techniques for percutaneous insertion of the
ortic valve. The results of this study may be particular for
he CoreValve Revalving System and may not be necessarily
eneralizable to other transcatheter prosthetic valves. Fur-
her studies are needed to assess predictors and the clinical
onsequences of conduction abnormalities following percu-
aneous aortic valvar insertion.
onclusions
n 2007, the first 2 percutaneous heart valve therapy devices
ained CE marking for marketing in Europe. The year 2008
ill mark the first full year of commercial availability of
ercutaneous aortic valve replacement, with more than
,500 implantations expected to occur. In this study, there
as a significant increase in the frequency of LBBB after
ercutaneous insertion of the aortic valvar prosthesis. Fur-
hermore, patients with right bundle branch block before
he procedure may be at risk for the development of
omplete heart block and subsequent need for pacing.
roper positioning of the prosthesis within the left ventric-
lar outflow tract may limit these risks. Physicians caring for
atients undergoing percutaneous aortic valve replacement
hould be aware of these potential complications.
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